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Key point
Surgical resection is the
only potentially curative
option for iCCA. Survival
after resection ranges
between 25%–40% at 5
years.
ReviewSummary
The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing worldwide. Although several
advances have been made in the past decades to better understand this complex malignancy and to
develop new treatment strategies, the prognosis of iCCA remains dismal. Liver resection (LR) is the
mainstay of treatment but only a minority of patients are amenable to surgery. In most cases, patients
with iCCA will require a major hepatectomy for complete resection of the tumour. This may be contra-
indicated or increase the surgical burden in patients with chronic liver disease and small remnant liver
volume. Lymphadenectomy with a minimal harvest of 6 lymph nodes is considered adequate, as
microscopic nodal metastases have been shown in more than 40% of patients. Current 5-year overall
survival following LR is in the range of 25%–40%. For locally advanced disease not amenable to upfront LR,
neoadjuvant locoregional therapies may be used with the aim of converting these patients to resect-
ability or even to transplantation in well-selected cases. Recent studies have shown that liver trans-
plantation (LT) might be a treatment option for patients with unresectable very-early iCCA (i.e. <−2 cm),
with survival outcomes comparable to those of hepatocellular carcinoma. In patients with unresectable,
advanced tumours, confined to the liver who achieve sustained response to neoadjuvant treatment, LT
may be considered an option within prospective protocols. The role of adjuvant therapies in iCCA is still
under debate. Herein, we review the recent advances in the surgical treatment of iCCA and examine its
correlation with locoregional therapies, adjuvant and neo-adjuvant strategies.
© 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Introduction
Intrahepatic cholangiocarcinoma (iCCA) arises
from the intrahepatic bile ducts proximal to the
second-order division. Its incidence has been rising
in the last few decades.1 Between 2003 and 2009,
an annual 5.9% increase in the incidence of iCCA
was reported in the United States.2 This sustained
increase throughout all ages and ethnicity strata3
has also been seen in European countries,4–6 par-
alleled by an increase in iCCA-specific mortality.7
Negative trends in iCCA incidence and mortality
could be partially explained by improved diagnosis
tools, more specific classification and increases in
risk factors such as chronic hepatitis, metabolic
syndrome and obesity.8 iCCA has therefore become
a significant healthcare problem for hepatologists
and surgeons.
Currently, the only widely accepted curative
treatment for iCCA is liver resection (LR). Although
the boundaries of surgical indications for iCCA have
been pushed by recent advances in technique and
perioperative management, evenwith the best care
most patients with iCCA will be dead within 3
years of diagnosis. Overall, the probability of being
cured by LR is 9.7%, with patients only reaching a
95% certainty of cure 9.5 years after resection.9Journal of Hepatology 2020 vol. 72 j 3Refinements to iCCA diagnosis and better un-
derstanding of genetic profiles might lead to opti-
mised surgical approaches, either by LR or liver
transplantation (LT). Moreover, combinations of
surgery with locoregional therapies and novel
drugs such as checkpoint inhibitors and molecular-
targeted molecules might result in opportunities to
use new adjuvant and neoadjuvant treatments.
This review aims to analyze the recent advances
in iCCA treatment focusing on surgical therapies
and highlighting perioperative strategies to
improve surgical outcomes.
Clinical diagnosis and general principles
of surgical consideration of iCCA
Most patients with iCCA do not have specific
symptoms and a liver mass is often discovered
incidentally during evaluation for an unrelated
reason. Amongst patients with symptoms, abdom-
inal pain is the most frequently reported. Weight
loss and malaise are often symptoms of more
advanced disease. Early jaundice is uncommon but
can occur when the tumour is located centrally
within the liver and obstructs the confluence of the
hepatic ducts byextrinsic compressionorbydirectly64–377
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j.jhep.2019.11.020extending into the biliary tree. In 1 study, serum
bilirubin >1.2 mg/dl was found to predict unresect-
able disease.10 Consequently, unless discovered
incidentally or in a screening programme, most
patients present with advanced tumours: an anal-
ysis of the SEER database between 1983 and 2010
confirmed that only 15% of patients with iCCA un-
derwent resection.11
Contrast-enhanced CT or MRI scans can often
show characteristics suggestive of iCCA, but
currently there are no accepted criteria for definitive
non-invasive diagnosis based on imaging alone. On
contrast-enhanced imaging, iCCA often presents as a
mass with irregular borders, peripheral rim
enhancement on the arterial phase and progressive
fillingof thecentral portionof the tumourondelayed
phases.12 CT and MRI scans may also demonstrate
capsular retraction and obstruction of segmental
biliary radicals proximal to the tumour. However,
smaller tumours are less likely to demonstrate these
specific features and may be difficult to distinguish
from hepatocellular carcinoma (HCC), especially in
the context of chronic liver diseases.
Tumour markers are of little help in the diag-
nostic setting. The majority of patients affected by
iCCA have increased levels of CA19.9 and various
cut-offs of CA19.9 serum levels (from 100 to 500
ng/ml) correlated with more advanced tumours,
unresectability and poor survival.13
Although tissue diagnosis is recommended to
establish a diagnosis of iCCA, in patients with
resectable lesions suspected of having chol-
angiocarcinoma, in which a metastatic spread has
been reasonably ruled out, a liver biopsy is generally
avoided because of the risk of seeding.14 Further-
more, even with a tissue biopsy demonstrating
adenocarcinoma, uncertainties remain in dis-
tinguishing iCCA from metastases arising from the
colorectum, oesophagous, stomach, pancreas and
lung.15 Currently, National Comprehensive Cancer
Network (NCCN) guidelines recommend upper and
lower endoscopy to rule out an occult primary in the
gastrointestinal tract.16 Likewise, distinguishing
iCCA frommixed cholangiocarcinoma-HCC requires
expert pathological review.
Due to the difficulties in differential diagnosis
between iCCA and liver metastases, fluorodeox-
yglucose positron emission tomography (FDG-PET)
is also commonly used to rule out a primary
tumour. Its staging role for the identification of
distant metastases is less well defined, although a
few small series showed that FDG-PET may detect
occult metastatic spread in up to 20–30% of cases.
Despite a recent meta-analysis supporting the role
of FDG-PET in the assessment of distant and nodal
disease in biliary tract cancers – it led to a change
in management in 15% of patients – current
guidelines do not recommend its routine use in the
absence of radiological or clinical suspicion of
metastatic disease.17,18Journal oIn addition to their diagnostic role, contrast-
enhanced CT or MRI are essential for determining
the extent of locoregional disease and metastatic
spread in order to assess resectability. Both CT and
MRI scans have good discriminatory ability in
assessing portal and arterial invasion, with mag-
netic resonance cholangio-pancreatography prop-
erly defining biliary anatomy and tumour
involvement. Nevertheless, digital preoperative
imaging assessment of lymph node metastases
remains poor. Very few studies assessed the role of
FDG-PET for the evaluation of nodal status, and no
recommendations can be drawn because of con-
flicting results.19 Given the high prognostic impact
of positive lymph nodes in patients with large
tumour burden or at increased surgical risk, pre-
operative endoscopic ultrasound with fine needle
aspiration cytology may be considered to drive
clinical decisions. Lymph node metastases beyond
the hepato-duodenal and gastro-hepatic ligaments
are a well-established contraindication to surgical
resection. Although positive lymph nodes confined
to the hepatic hilum are also associated with high
rates of recurrence, long-term survival in up to 15%
of cases is still possible after tumour removal with
locoregional lymphadenectomy; this makes resec-
tion in the presence of nodal tumour spread an
individualised decision to be taken after careful
risk-benefit analysis.
In patients with underlying liver disease,
assessment of portal hypertension is critical as its
presence is usually a contraindication to LR. In
addition, size and quality of the liver remnant after
resection are critical factors, as atrophy and fibrosis
from biliary obstruction or steatosis and chronic
damage can result in liver remnants that are unable
to regenerate after surgery, leading to a high risk of
post-operative liver failure. Peritoneal or distant
metastases are other general contraindications to
resection.
Conventional surgical aims of LR should be:
complete tumour resection with free margins (i.e.
R0 resection) and preservation of enough liver
volume to avoid post-operative liver failure. As the
majority of patients are referred to surgery at a
locally advanced stage and/or with extrahepatic
disease, only 12–40% of all patients with iCCA are
candidates for surgical resection at the time of
diagnosis.1,20,21
The multifaceted concept of resectability
in iCCA
Resectability depends on 2 main variables: the
location of the tumour lesion, including its rela-
tionship with intrahepatic vascular and biliary
structures, and the amount and quality of the liver
parenchyma remaining after tumour resection.
Concerning the topographic definition of iCCA,
atypical or anatomical resections can be performedf Hepatology 2020 vol. 72 j 364–377 365
ALPPSPVE/PVL
4-8
weeks
6-10
days
Stage I
Stage II
X
X
Fig. 1. Regenerative techniques for the future liver remnant to expand iCCA resectability
(slow vs. fast techniques have various indication and outcomes; see text). ALPPS, associating
liver partition and portal vein ligation for staged hepatectomy; iCCA, intrahepatic chol-
angiocarcinoma; PVE, portal vein embolisation; PVL, portal vein ligation. The knife indicates the
time of liver transection.
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while anatomic hepatectomies are mostly per-
formed for large multisegmental tumours. A recent
propensity-score matching analysis has demon-
strated better survival and lower recurrence rates
after anatomical resections.22 Overall, due to
advanced disease stage at diagnosis, most patients
(70–80%) will require a major hepatectomy (i.e. >−3
segments resected) to achieve complete resection.
Fifty to 70% of patientswith resectable iCCAundergo
hemi-hepatectomyor extendedhepatectomy.20,23,24
For centrally located lesions, the surgical plan-
ning is often complex, due to the relationship of
the lesion with the first- and second-order portal
and biliary branches, as well as with suprahepatic
veins. In such instances – as for perihilar chol-
angiocarcinoma – a bilateral involvement of
second-order biliary branches, a unilateral liver
atrophy with contralateral biliary or vascular
involvement (either portal or arterial) or a unilat-
eral biliary involvement with contralateral vascular
involvement (either portal or arterial) contraindi-
cate LR. Additionally, these patients may present
jaundice (15% of all iCCA) and need to undergo
prompt endoscopic or percutaneous drainage
before any treatment decision can be made.
Notably, the presence of jaundice impairs liver
function and, together with a consistent risk of
cholangitis, worsens the surgical outcome. LR
associated with biliary tree resection is indicated inJournal of Hepatology 2020 vol. 72 j 3tumours invading the ductal bifurcation and/or the
main hepatic duct, as required in 20%–30% of
hepatectomies for iCCA.23,24 In a recent multi-
institutional analysis of 128 patients who under-
went major vascular resections of the inferior vena
cava and portal vein (21 and 98 patients, respec-
tively), the perioperative outcomes were compa-
rable to those achieved in 959 cases of
conventional resection, suggesting that major
vascular resections and reconstructions can be
considered in properly selected patients, if R0
margin can be achieved.25,26
Concerning the recommended future liver
remnant (FLR) volume, iCCA does not differ from
other indications for LR, with a threshold of 25% of
liver volume to be preserved for patients with
normal parenchyma. Conversely, patients with
iCCA in the context of chronic liver disease will
require a minimum FLR of 40% with no portal hy-
pertension. The higher threshold in case of chronic
liver diseases makes the surgical option even less
likely in this subgroup, representing up to 20% of
patients with iCCA.27
Management of the future liver remnant
In cases with an anticipated inadequate FLR,
regenerative techniques may be used in order to
expand resectability (Fig. 1).
 Portal vein embolisation (PVE) by preoperative
radiological injection of embolic agents in the
right portal system is a safe technique that
enables FLR hypertrophy of around 40% in the
healthy liver after a median of 4 weeks. Portal
embolisation, however, is burdened by 20–30%
drop-out rates due to tumour progression or
insufficient regeneration. Particularly in the
cirrhotic or cholestatic liver, regeneration is
impaired, and levels of FLR hypertrophy as low
as 9% have been reported.28
 In patients with very low FLR volume and those
expected to have insufficient regeneration after
PVE or to be at a high risk of tumour progression
(possibly impairing the chances of surgical
resection during the regeneration phase) an
accelerated procedure called associating liver
partition and portal vein ligation for staged
hepatectomy (ALPPS) may allow for faster and
enhanced hypertrophy of the liver remnant (up
to 70%) compared to conventional portal em-
bolisation.29 ALPPS, however, is limited by
morbidity rates above50%andmortality rates as
high as 20%. In addition, patients affected by
biliary tumours are exposed to worse perioper-
ative outcomes with ALPPS, which may be
related toprevious cholestasis and/or associated
severe steatosis and chronic liver damage.30Staging laparoscopy
For patients who are candidates for extensive sur-
gical procedures, at high surgical risk or with64–377
Key point
Hilar lymphadenectomy
(minimum of 6 resected
lymph nodes) provides
prognostic information and
assists in risk stratification
for adjuvant trials.advanced tumours (i.e. multifocal disease, high
CA19.9 level, suspected lymph node spread or
vascular invasion), exploratory laparoscopy and
intraoperative ultrasound may be indicated in or-
der to rule out peritoneal spread, distant lymph
node or multifocal intrahepatic diffusion. Yields of
between 27–38% have been reported for the iden-
tification of peritoneal or intrahepatic metastases
that preclude resection.17
Multifocal disease
Multifocal iCCA is seen in nearly 50% of pa-
tients31,32 and the role of surgery for these patients
remains debatable. Patients with multifocal iCCA
are at an increased risk of tumour recurrence and
death after LR compared to patients with a single
lesion.20,32,33 The adverse effect is still evident even
compared to patients with a single large tumour
(>7 cm).31 To account for such prognostic impact,
the American Joint Committee on Cancer (AJCC)
has classified multifocal tumours as T2 stage, along
with single tumours with vascular invasion.34 In
these patients, LR does not seem to improve overall
and recurrence-free survival compared to locore-
gional therapies.35
Death is related to intrahepatic tumour spread
in the majority of cases with multifocal iCCA, so
both locoregional and surgical therapies may be of
help in selected patients. In this respect, Interna-
tional Liver Cancer Association (ILCA) guidelines
support non-curative resections in patients with
resectable multinodular disease or macrovascular
invasion. In the future, a reasonable approach not
included in the current guidelines may consider
the response to locoregional therapies as a selec-
tion tool for patients with iCCA who may benefit
from LR, despite initial presentation.
Role of lymphadenectomy
The role of hilar lymphadenectomy in iCCA is still
under debate. Nodal metastases are found in up to
45% of patients and are known to be one of the
most important prognostic factors after LR for
iCCA.36,37 NCCN and ILCA guidelines recommend
lymphadenectomy with a minimum of 6 nodes
harvested.27 These recommendations are likely
responsible for the increase in frequency and
number of nodes removed during hepatectomy for
iCCA in the last few years,38,39 with several authors
performing routine lymphadenectomy in order to
achieve more precise staging of nodal status and to
decrease the risk of local recurrence.40,41 This is
even more important considering the low detec-
tion rate of positive lymph nodes at imaging.42
Contrary to the general trend, a few series have
reported that routine lymphadenectomy does not
directly impact on patient survival.41,43–45
A recent case series from 15 Western and
Eastern centres showed that lymphadenectomy
was performed in less than 50% of patients un-
dergoing LR for iCCA.39 Among patients whoJournal ounderwent lymphadenectomy, nearly 80% had a
complete hilar lymphadenectomy performed. A
median of 4 lymph nodes (IQR 4–8) were harvested
and 43% of them were positive for metastatic iCCA.
Interestingly, this study showed that patients who
had >−3 lymph nodes resected had better survival
than those who had only 1–2 nodes removed. The
AJCC staging system recently included the recom-
mendation of a minimum of 6 lymph nodes to
ensure accurate nodal staging.34
In cirrhotic patients, however, lymphadenec-
tomy is associated with a complication rate of up to
71%, limiting the role of lymphadenectomy to
selected cases.
Patients with positive lymph nodes may benefit
from adjuvant therapies. With the advent of more
effective adjuvant protocols, it is expected that
precise nodal staging will become more important
in the near future.
Minimally invasive surgery for iCCA
Laparoscopic LR is associated with better short-
term outcomes, improved pain management and
shorter hospital stay,46 but few studies assessed
the role of minimally invasive surgery specifically
in iCCA. A propensity-matched cohort study
comparing laparoscopic to open LR showed similar
outcomes between groups, with a median disease-
free survival of 33 months for the laparoscopic
group and 36 months for the open surgery group.47
Similar results were also reported by other
authors.48
Although the use of robotic technology has not
been specifically evaluated for iCCA, encouraging
results have been reported in a cohort of patients
with different types of hepatic tumours treated by
hepatectomy.49 A recent consensus states that ro-
botic LR is safe and has similar effectiveness to
open hepatectomy in patients with hepatic malig-
nances, although the level of evidence supporting
this assertion is very low.50
Results of liver resection for iCCA
Even though only a minority of patients with iCCA
are candidates for LR, the number of hepatectomies
for iCCA is increasing worldwide.51 This is related
to technical advances in the field of hepatobiliary
surgery, improved perioperative management and
more focused consideration of iCCA in which sus-
tained responses can be achieved by means of
locoregional and systemic therapies. In high-
volume hepatobiliary centres, surgical mortality
after iCCA resection is reported to be lower than
5%.24 Table 1 gives a literature overview of the
observed outcomes after LR for iCCA.
The median overall survival after LR is reported
to be 40 months, with a 5-year overall survival of
25–40%.20,52,53 Tumour recurrence occurs in about
50–70% of patients at a median time of 26 months.
A meta-analysis on curative resection for iCCA
identified age (HR 1.10; 95% CI 1.03–1.17), tumourf Hepatology 2020 vol. 72 j 364–377 367
Key point
Downstaging treatments
aimed at conversion of
unresectable disease by
means of locoregional
therapies might be an op-
tion in patients with locally
advanced tumours and
good performance status.
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368size (HR 1.09; 95% CI 1.02–1.16), presence of mul-
tiple lesions (HR 1.70; 95% CI 1.43–2.02), lymph
node metastases (HR 2.09; 95% CI 1.80–2.43),
vascular invasion (HR 1.87; 95% CI 1.44–2.42) and
poorly differentiated tumours (HR 1.41; 95% CI
1.17–1.71) as significant predictors of tumour
recurrence and patient death.33
Repeated resection for treatment of intrahepatic
recurrence
The liver is the most frequent site of recurrence
following LR for iCCA, with exclusive intrahepatic
disease found in about 60% of cases.54,55 These
finding have supported the use of repeated hepa-
tectomy in those cases with a tendency to recur
only in the liver.
In such a context, if R0 resection is achievable,
patient outcomes can be improved significantly
with LR. In a multicentric study, 41 repeated re-
sections were performed among 400 recurrent
cases, with a median survival of 26.1 months
compared to 9.6 and 16.8 months in patients with
liver-recurrent iCCA treated with intra-arterial
therapy or standard chemotherapy, respectively.56
Other studies reported a 5-year survival of 63.7%
by means of resection and ablation in 103 out of
406 liver-only recurrent iCCAs. Although a clear
selection bias affects retrospective studies, it
should be emphasised that surgery is a viable op-
tion for recurrent iCCA with no sign of extrahepatic
spread. While specific biologic markers able to
single out such patients upfront are an unmet need
from both the perspective of resection and trans-
plantation, repeated surgical resection, if techni-
cally feasible, may offer competitive survival with
respect to the currently available non-surgical
therapies.
Role of neoadjuvant therapies from a surgical
perspective
There is no evidence supporting the use of neo-
adjuvant systemic chemotherapy over upfront
resection in patients with resectable iCCA. How-
ever, the rationale for preoperative treatment
aimed at decreasing the high recurrence rates and
downstaging initially unresectable disease is
strong, especially considering the low resectability
rates of iCCA, the high incidence of R1 resections
and the significant surgical morbidity burden,
often impairing the possibility of adjuvant treat-
ments. Although randomised studies supporting
neoadjuvant chemotherapy in iCCA are lacking, the
use of preoperative treatments to downstage tu-
mours is part of general practice, and positive
outcomes have been reported in retrospective se-
ries of patients with iCCA, preserved liver function
and no cholestasis.
In an Eastern series, 22 patients with unresect-
able iCCA who received neoadjuvant gemcitabine
were downstaged to resection and achieved a 5-
year overall survival of 45%.57 In a Western study,Journal of Hepatology 2020 vol. 72 j 374 patients with locally advanced unresectable
iCCA initially treated with chemotherapy (53% of
whom were successfully converted to resection)
were compared to patients with resectable iCCA
who underwent surgery alone58: postoperative
morbidity and mortality were similar, as well as
median survival after surgery (24 months vs. 26
months, respectively: p = 0.39). Neoadjuvant
locoregional therapies are increasingly used for
iCCA, although reliable data on the efficacy of such
approaches are scarce and at times disappointing.
Discouraging conversion rates to surgery have
been observed in 8 out of 104 patients treated with
hepatic artery infusion chemotherapy;59 in another
study, none of 12 patients prospectively treated
with a combination of selective intra-arterial flox-
uridine with systemic cisplatin and gemcitabine
became resectable.60 Pre-surgical selective internal
radiation therapy (SIRT) in iCCA has shown prom-
ising preliminary results in terms of safety and
effectiveness,61,62 even in association with chemo-
therapy, in the treatment of advanced iCCA.63 In a
study on 45 patients with unresectable iCCA,
Yttrium90 (Y90) SIRT combined with gemcitabine
and/or platinum chemotherapy achieved an 18%
rate of conversion to free-margin surgery with no
significant toxicity.62 An example of efficacy of such
combination treatment is presented in Fig. 2.
Although transarterial chemoembolisation
(TACE) has proven to be effective for disease con-
trol in the advanced setting, few reports are avail-
able on its role in the neoadjuvant setting. To date,
TACE has conferred disappointing response rates of
around 20% in patients with unresectable iCCA,
which are inferior to those of intra-arterial
chemotherapy and SIRT. This is possibly a conse-
quence of the hypovascular nature of iCCA, which
is characterised by extensive fibrosis and a pre-
dominantly non-arterial blood supply.64
External-beam radiation therapy in combina-
tion with systemic chemotherapy has also been
proposed.65 In a recent Japanese study of 15
consecutive patients, 9 were successfully down-
staged to R0 resection (60%) with a 5-year overall
survival of 24%.66
Liver transplantation for iCCA
iCCA has been a contraindication for LT in most
centres worldwide due to very poor initial results,
with 2-year survival of around 30%.67–69 The lack of
standardised patient selection and the absence of
neoadjuvant therapies likely impacted on out-
comes. The landscape started to change after se-
lection criteria were proven to be essential to
improving survival in LT for early-stage HCC.70 The
excellent survival obtained in hilar chol-
angiocarcinoma thanks to careful patient selection
and to neoadjuvant chemo-radiation protocols,
together with the new oncological indications for
transplant opened up by the advent of direct-
acting antiviral agents for treatment of HCV64–377
Table 1. Outcomes of liver resection for patients with intrahepatic cholangiocarcinoma: literature review.
Study Year Study design n
Perioperative
mortality*
Overall survival (%)
DFS (%)
5-year
Neoadjuvant
treatment
Adjuvant
treatment Comments1-year 3-year 5-year
Weber et al.40 2001 Retrospective single centre 33 3% n.a. 55 31 22% (3y) none none 62% resectability rate
Jensen et al.51 2008 Retrospective multicentre 446 8.0% 68 n.a. 18 n.a. n.a. n.a. 12% resectability rate
De Jong et al.20 2011 Retrospective multicentre 449 5.7% 77 44 31 n.a. none none –
Sotiropoulos et al.23 2009 Retrospective single centre 41 n.a. 90 68 44 25 none none Non-cirrhotic and R0
resections only
Endo et al.24 2008 Retrospective single centre 82 1.2% n.a. n.a. n.a. median
36 months
5 patients
converted to
resection
case-by-case
basis
–
Konstadoulakis et al.87 2008 Retrospective single centre 54 2.0% 80 49 25 n.a. none none –
Lang et al.88 2009 Retrospective single centre 83 7% 71 38 21 30 (in 53 R0
resections)
none none –
Nakagohri et al.89 2008 Retrospective single centre 56 8.9% 59 42 32 n.a. none none –
Shimada et al.41 2009 Retrospective single centre 104 n.a. n.a. n.a. 33.7 n.a. none none –
Nakagawa et al.90 2005 Retrospective single centre 44 1.9% 66.2 38.3 26.3 n.a. none none –
Choi et al.91 2009 Retrospective single centre 64 n.a. 76.6 52.7 39.5 34.7 (3-year) none none –
Uenishi et al.92 2008 Retrospective multicentre 133 1.5% 63 36 29 - none none 66% recurrence
median follow-up
1.4 years
Paik et al.93 2008 Retrospective single centre 97 7.1% 74.9 51.8 31.1 2.1 none none –
Ohtsuka et al.94 2002 Retrospective single centre 48 n.a. 62 38 23 - none none 63% recurrence
median follow-up
70.8 months
Kim et al.43 2015 Retrospective single centre 102 LND
113 no LND
1.0%
0%
67.7
74.3
45.5
47.8
30.0
42.5
21.7
33.4
none yes –
Si et al.22 2019 Retrospective single centre 319 AR
383 NAR
4.4%
4.4%
72.9
62.0
45.7
30.8
36.0
25.3
28.1
18.0
none none –
AR, anatomical resection; DFS, disease-free survival; LND, lymphadenectomy; n.a.: not available; NAR, non-anatomical resection.
*Defined as death within 30 days from resection.
Journal
of
H
epatology
2020
vol.72
j364
–377
369
AC
B
Fig. 2. Major liver resection after downstaging of iCCA. Multifocal iCCA in a 71-year-old woman presenting with epigastric pain. (A) Large multifocal iCCA: at
diagnosis the main lesion of 7.5 cm infiltrates left and middle hepatic veins and is adherent to the right hepatic vein, left portal vein and the anterior branch of the
right portal vein. Satellite lesions in the left liver lobe are also present. (B) Partial response to neoadjuvant therapy with enlargement of the surgical margin on the
right hepatic vein (arrowhead): combination of first-line chemotherapy with gemcitabine+cisplatin and SIRT was administered and partial response was
observed (i.e. size reduction of the main lesion with detachment from the right hepatic vein adhesion and atrophy of the right anterior sector). The patient
underwent extended left hepatectomy including the right anterior sector (segments I-II-III-IV-V-VIII), with preservation of the posterior portal and biliary
pedicles. Adjuvant capecitabine was administered. She is alive and well 18 months after surgery. (C) Surgical specimen and postoperative CT scan showing
neoplastic thrombosis in the middle hepatic vein and the regenerated right posterior sector of the liver, left as the only functioning remnant parenchyma.
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Key point
Retrospective studies have
shown that liver trans-
plantation may offer
acceptable outcomes for
patients with unresectable
very-early iCCA (i.e. <−2 cm).
Key point
Combinations of neoadju-
vant therapies and liver
transplantation may also
be an option for patients
with locally advanced iCCA,
but prospective studies
with pre-determined se-
lection criteria are needed.infection, further contributed to LT being consid-
ered a treatment option for selected cases of iCCA.
After 2014, several retrospective cohorts have
showed satisfactory results after LT for iCCA, as
summarised in Table 2. The importance of patient
selection was first demonstrated in an interna-
tional multicentric study enrolling patients who
underwent LT with an occult iCCA found in the
explant. Authors showed that patients with a single
iCCA <−2 cm (very-early iCCA) had a 5-year overall
survival of 65% and a 5-year cumulative incidence
of recurrence of 18%. The outcomes in the very-
early iCCA group were far superior to those in pa-
tients with more advanced iCCA, who achieved a
disappointing 5-year overall survival of 45% and a
5-year cumulative incidence of recurrence of 65%.
These results suggest that LT might be an option for
patients with very-early iCCA who are not candi-
dates for LR (e.g. due to cirrhosis). As these results
need to be prospectively validated, a multicentric
single-arm clinical trial (NCT02878473) is under-
way to confirm the effectiveness of LT for very-
early iCCA.
Besides the rare indication of very-early and
unresectable iCCA and after exclusion of patients
with positive lymph nodes or distant metastases,
there remains a considerable subset of patients
with liver-only disease deemed unresectable due
to either local invasion of major vascular and
biliary structures or to inadequate liver remnant. In
such patients, the use of neoadjuvant protocols
followed by LT may be a viable option, following
careful patient selection based on risk stratification
and tumour biology.
The effectiveness of LT for patients with locally
advanced unresectable iCCAwas recently addressed
in a case series evaluating the use of neoadjuvant
chemotherapy in select patients with favourable
tumour biology.71 The studyenrolled patientswith a
biopsy proven iCCA >2 cm and no evidence of
extrahepatic disease, vascular invasion and lymph
node spread. A minimal period of 6 months with
sustained response after chemotherapy with gem-
citabine and cisplatin was mandatory. Out of 21
evaluated patients, 6 underwent LT and 1 was con-
verted to LR. Adjuvant therapy with gemcitabine,
capecitabine or bothwas recommended for patients
with active iCCA in the explants, starting 4–6 weeks
after LT. Despite the extensive tumour burden
detected in the explanted livers (median number of
4 lesions up to 7 cm), an excellent 5-year overall
survival rate of 83%with a recurrence rate of 50% at a
median of 7.6 months were shown. Such results
exceed those previously reported for either LR,
chemotherapy or LT alone, in the absence of neo-
adjuvant treatments.71
Clearly, tumour biology and related markers are
critical for proper patient selection; the role of
response to neoadjuvant protocols as a surrogate of
tumour aggressiveness is worth investigation.Journal oProspective clinical trials considering survival
endpoints from an intention-to-treat perspective
are necessary to evaluate LT as a treatment for
advanced iCCA in a modern setting, including
neoadjuvant radiotherapy and SIRT in association
with chemotherapy. Ideally, prospective series
should be followed by randomised trials to assess
the survival benefit of LT compared to optimal
locoregional and systemic treatment. However,
given the rarity of disease and the difficulties
associated with a randomised design for transplant
indications, prospective parallel studies of down-
staging treatments followed by LT versus palliative
treatment options may be proposed. Patient co-
horts should be matched based on tumour burden
and biological criteria, and the primary endpoint of
such studies should be the survival benefit, defined
as the difference in survival achieved by LT
compared to other options.
Based on prognostic information already avail-
able, future studies should also focus on pre-
determined morphologic and biologic criteria for
consideration of a transplant strategy. An example
of such an approach that combines downstaging
treatments and LT is shown in Fig. 3.
Table 3 summarises the current shared in-
dications and contraindications to LR and LT,
together with proposed approaches and future
perspectives.
Adjuvant therapies for iCCA
Adjuvant chemotherapy
Post-operative chemotherapy is not a stand-
ardised practice in iCCA. Given its relative rare-
ness, few studies addressed the role of adjuvant
chemotherapy exclusively in iCCA, while most
chemotherapy studies still gather all types of
biliary malignances. In addition, no study assessed
the effectiveness of adjuvant therapy after LT
for iCCA.
Overall, the available evidence is still poor. A
randomised phase III trial failed to prove the su-
periority of gemcitabine and oxaliplatin compared
to observation in patients with resected biliary
cancer (HR 0.72; 95% CI 0.43–1.97).72 The recent
BILCAP trial showed that adjuvant capecitabine
was associated with increased per-protocol overall
survival in patients with biliary malignances, but
failed to demonstrate this effect in the intention-
to-treat analysis.73 In the subgroup of 84 patients
with iCCA within the BILCAP trial, 43 were treated
with capecitabine while 41 belong to the observa-
tion group. At the end of 60-month follow-up, 56%
of patients with iCCAwere alive in the capecitabine
group whereas survival in the observation group
was 41%. However, such a trend did not reach
statistical significance (HR 0.65; 95% CI 0.35–1.18).
A meta-analysis of retrospective cohorts
showed that patients with resected iCCA who un-
derwent adjuvant intra-arterial chemotherapy hadf Hepatology 2020 vol. 72 j 364–377 371
Table 2. Outcomes of liver transplantation for patients with intrahepatic cholangiocarcinoma: literature review.
Study Year Study design n
Overall survival (%)
DFS (%)
5-year
Neoadjuvant
treatment
Adjuvant
treatment Comments1-year 3-year 5-year
Sotiropoulos et al.95 2008 Retrospective 10 70 50 33 – none none –
Vallin et al.96 2013 Retrospective
Multicentre
10 80 60 24 – none none –
Sapisochin et al.97 2014 Retrospective
Multicentre
27 78 66 51 36 none none –
Facciuto et al.98 2015 Retrospective 7 iCCA
9 iCCA+HCC
16 iCCA-HCC
71 – 57 44 none none –
Vilchez et al.99 2016 Retrospective
Multicentre
440 79 58 47 – none none –
Sapisochin et al.100 2016 Retrospective
Multicentre
15 single <−2 cm
33 multiple
or >2 cm
93
79
84
50
65
45
82
39
none none –
O'Grady et al.101 1988 Retrospective 13 iCCA 38 10 10 no none none –
Yokoyama et al.102 1990 Retrospective 2 50 0 – – none none –
Meyer et al.103 2000 Retrospective
Multicentre
207 72 48 23 – none ~10% of
patients
84% DFS at
25 months.
Shimoda et al.104 2001 Retrospective 16 62 39 – 35 none none 8 patients with
iCCA-HCC.
Robles et al.105 2004 Retrospective
Multicentre
23 77 65 42 – none none 2-year DFS 35%
Ghali et al.106 2005 Retrospective
Multicentre
10 – 30 – – none none 1 patient with
iCCA-HCC
Hong et al.107 2011 Retrospective
LR vs. LT
LT: 25
LR: 12
– 38 32 33 9 LT no LR 16 LT and
5 LR
–
Lunsford et al.71 2018 Prospective
single-arm
12 enrolled
6 underwent LT
100 83.3 83.3 50 Chemotherapy
+ 6-month
mandatory SD
none –
DFS, disease-free survival; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; iCCA-HCC, mixed hepatocellular cholangiocarcinoma; LR, liver resection; LT,
liver transplantation; SD, stable disease.
Key point
Adjuvant chemotherapy is
recommended in high-risk
patients (multifocal dis-
ease, large lesions, positive
lymph nodes or R1 resec-
tion); capecitabine for 6
months has demonstrated
a survival advantage over
placebo.
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372a survival benefit (HR 0.66; 95% CI 0.55–0.79), even
though the risk of bias was high (I2 = 0.20).74 An
American Society of Clinical Oncology (ASCO)
expert panel conducted a systematic review to
guide decision-making for patients with resected
biliary cancer and concluded that adjuvant cape-
citabine should be offered.75
Targeting molecular profile of iCCA: implication
for the surgical context
As reported in other chapters of this special issue
on liver cancer, novel concepts in iCCA pathology
and genomics have shown important biological
differences between iCCA and other types of
biliary cancers.76 Such a revolution in our under-
standing of iCCA biology is ongoing and likely to
influence future trials specifically focused on this
cancer.
Understanding gene aberrations in iCCA may
provide insights on post-resection prognosis and
identify potential targets for novel therapies.
Nearly 40% of patients with biliary cancer have
potentially targetable mutations77 with some
recurrent mutations identified in IDH1, IDH2,
FGFR1, FGFR2, FGFR3, EPHA2, and BAP1 genes. Of
note, the mutation on FGFR2 was found exclusively
in iCCA, at reported rates of around 15%.77 This type
of genetic signature likely contributes to a more
favourable biological behaviour,76 as patients with
FGFR had significantly higher overall survival (37Journal of Hepatology 2020 vol. 72 j 3months vs. 20 months) compared to non-mutated
patients.78 In such a context, infigratinib, dera-
zantinib and pemigatinib showed overall response
rates of 19%, 21% and 36%, and disease control rates
of 83%, 83% and 82%, respectively, even though
progression-free survival remains around 6
months, mainly due to primary and secondary
resistance.79–81 These small molecules evaluated in
phase II trials for advanced iCCA may possibly
represent future alternative options in the adjuvant
setting in light of premiminary data on their
manageable toxicity.
The IDH1 pathway is deranged in up to 25% of
patients with iCCA and a recent phase II trial with
ivosidenib (AGI-120) in second-line demonstrated
encouraging results.82,83 BRAF is another rare
targetable mutation involving 5–7% of iCCA and a
trial with dabrafenib and trametinib for these pa-
tients is currently underway. The inhibition of heat-
shock protein 90 has also recently been shown as
an alternative target for tumours with FGFR aber-
rations.84 Until now, the results of immunotherapy
have been disappointing, with clinical response
confined to the small subset of patients with mi-
crosatellite instability (0.5–2.5% of cases).
Although further insights on the prognostic
relevance of mutations in iCCA are needed, a role
for patient selection and treatment allocation
also based on molecular prognostic assessment
may be foreseen in the future. Molecular studies64–377
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Fig. 3. Liver transplantation after sustained response to neoadjuvant combined treatment. Large, single iCCA in a 58-year-old woman with preserved liver
function and metabolic syndrome. (A) Large iCCA: at diagnosis the CT scan shows tumour involving the hepato-caval confluence, with invasion of the right
hepatic vein, infiltration of the inferior vena cava together with the middle and left hepatic vein common trunk. The tumour is adherent to portal bifurcation and
biliary confluence. The patient underwent first-line chemotherapy with gemcitabin and cisplatin (4 courses) followed by Y90 radioembolisation. (B) Sustained
tissue response after neoadjuvant treatment: partial response was observed with extensive necrosis of the liver lesion, remaining stable in size for 6 months. After
4 additional months, liver transplantation was performed under a prospective protocol using a graft of marginal quality. The patient is alive and free of recurrence
2 years after transplant. (C) In the explanted liver, extensive fibrosis of 70% of the tumour, necrosis and inflammatory infiltrate (arrow) were detected with
residual tumour nests in its context (arrowhead), focally infiltrating the vena cava and the right hepatic vein. Middle and left hepatic veins were encased but not
invaded. Portal vein thrombosis was not neoplastic.to elucidate resistance mechanisms and trials
evaluating sequential or combination treatments
with other TKIs, immunotherapy or chemo-
therapy are also needed in order to improve
outcomes. All in all, molecular characterisation of
iCCA will play an important role in the context ofJournal opre- and post-surgical management of patients
with iCCA.
Adjuvant radiation therapy
Few studies assessed the role of adjuvant radiation
therapy for iCCA. One retrospective series showedf Hepatology 2020 vol. 72 j 364–377 373
Table 3. Summary of indications and eligibility criteria for liver resection and liver transplantation in iCCA.
Liver resection Liver transplantation
Age, PS, comorbidities Case-by-case evaluation to be balanced with resect
ability criteria based on extent of liver tissue to be
removed vs. volume and function of the liver remnant
<65 years, absence of comorbidities contraindicating LT
Histology confirmation Recommended Mandatory
Ca19.9 Relative contraindication for Ca19.9 >500 ng/ml in the absence
of jaundice
To be defined
Tumour staging Single resectable mass any size, if resectability is
provided according to point 1
Unilateral multifocal disease
Unresectable <2 cm very-early tumour arisen in chronic
liver disease/cirrhosis (i.e. solid data available and trial
ongoing)
Unresectable >2 cm lesion with sustained response to
chemotherapy ± RT (experimental, within prospective
protocols)
Chronic liver
disease/cirrhosis/PH
Relative/absolute contraindication No limitation regarding liver function
Macrovascular invasion Relative contraindication (vascular reconstructions are allowed
if R0 resection is achievable)
Contraindication in case of intra-/extrahepatic vascular
invasion. Questionable in case of extravascular growth
with encasement of major inflow/outflow tributaries
(experimental)
Preoperative lymph
node assessment
Recommended Mandatory to rule out nodal disease
Multifocality* Relative contraindication To be defined.
Neoadjuvant treatment Experimental Very-early iCCA: experimental
Advanced iCCA: recommended as selection tool
(sustained responses may be selected for transplant
consideration)
Additional procedures PVE, ALPPS and biliary reconstructions can be added, though
associated to higher morbidity/mortality
DCD, marginal grafts in pts with preserved liver function
and LDLT can be proposed
Adjuvant treatment Advisable in high-risk patients To be defined
Future studies - Prospective investigations on neoadjuvant “downstaging”
chemotherapy ± targeted agents ± RT (EBRT vs. SIRT) schemes
able to convert advanced liver-only tumours to resectability
- Prospective randomised investigations on adjuvant CT in R1
resections and in patients at high risk of
recurrence
Prospective parallel studies with matched patients co-
horts (based on tumour burden and biology) to assess
survival benefit of LT (± downstaging treatments) vs.
other treatment options
Study endpoints OS, RFS Transplant benefit, OS (ITT), RFS and cancer-related
survival
ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; DCD, donor after cardiac death; EBRT, external-beam radiotherapy; iCCA, intrahepatic
cholangiocarcinoma; ITT, intention-to-treat; LDLT, living donor liver transplantation; LT, liver transplantation; PS, performance status; PVE, portal vein embolisation; OS,
overall survival; RFS, recurrence-free survival; RT, radiotherapy; SIRT, selective internal radiotherapy.
*Satellite lesions (nodules <1 cm at <1 cm from the main tumour) may be considered part of the main tumour while satellite nodules at >1 cm distance from the main tumour
and/or in different liver segments considered true multifocal disease.
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374that adjuvant radiation therapywas associatedwith
improved survival compared to LR alone (HR 0.78;
95% CI 0.67–0.92).85 Another report suggested that
systemic chemotherapy plus radiation therapy may
confer a greater benefit than chemotherapy alone in
patients with resected iCCA. In a retrospective study
of patients with positive margins, radiation therapy
did not impact on outcomes.86 Based on the paucity
of data, the recent ASCO guidelines do not recom-
mend radiation therapy for patients who have un-
dergone R1 resections for iCCA.75
Conclusions
Hepatic resection is the only treatment able to
confer long-term survival in patients with iCCA,
even though the overall prognosis of resected pa-
tients remains dismal. Unfortunately, the majority
of resections are offered to patients with advanced
tumour stages. New strategies for tumour down-
staging through neoadjuvant systemic or locore-
gional treatments combined with advanced
surgical procedures including liver regenerationJournal of Hepatology 2020 vol. 72 j 3techniques and vascular reconstructions have
enhanced the resectability of iCCAs.
For selected patients with exclusive liver disease,
LT could be a viable option, either in early stages
diagnosed in the context of chronic liver diseases or
in locally advanced tumours, when neoadjuvant
treatments have achieved sustained tumour
response without extrahepatic tumour spread. On
top of locoregional therapies and radiation therapy
through intra-arterial or external-beam approaches,
molecular profiling of iCCA is likely to provide
improved prognostic assessment, more precise se-
lection for surgical intervention and objective
stratification of risk of recurrence to be counteracted
by specifically designed adjuvant treatments.
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